Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Common Equity (2020 - 2026)

NeuroPace has reported Common Equity over the past 7 years, most recently at $14.5 million for Q1 2026.

  • For Q1 2026, Common Equity fell 40.44% year-over-year to $14.5 million; the TTM value through Mar 2026 reached $14.5 million, down 40.44%, while the annual FY2025 figure was $19.0 million, 137.5% up from the prior year.
  • Common Equity for Q1 2026 was $14.5 million at NeuroPace, down from $19.0 million in the prior quarter.
  • Over five years, Common Equity peaked at $62.8 million in Q1 2022 and troughed at $8.0 million in Q4 2024.
  • A 5-year average of $24.6 million and a median of $19.4 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: soared 140.16% in 2022 and later crashed 62.31% in 2023.
  • Year by year, Common Equity stood at $34.8 million in 2022, then tumbled by 40.61% to $20.7 million in 2023, then tumbled by 61.2% to $8.0 million in 2024, then surged by 137.5% to $19.0 million in 2025, then decreased by 24.05% to $14.5 million in 2026.
  • Business Quant data shows Common Equity for NPCE at $14.5 million in Q1 2026, $19.0 million in Q4 2025, and $18.5 million in Q3 2025.